Topic:

Venture Capital

Latest Headlines

Latest Headlines

Allied Minds' SciFluor banks $30M to get into the clinic

SciFluor Life Sciences, a graduate of the Allied Minds startup factory, raised $30 million to get its fluorine-based candidates into clinical development.

Gene therapy player Dimension stirs IPO buzz with $65M venture round

Demonstrating once again that gene therapy research has emerged as one of the hottest fields in biotech, Cambridge, MA-based Dimension Therapeutics has rounded up a $65 million B round from a slate of new and existing investors. Adding in Bayer's $20 million upfront for signing on as a partner last summer along with its A round, Dimension has now banked more than $100 million for its R&D activities. The only question now is whether it will wait long to file an IPO.

Biotech venture investing continues to sizzle in a big, $1.7B Q1

With crossover investors still crowding into the biotech field to help launch a wave of new IPOs, the industry recorded $1.7 billion in new venture funds in the first quarter, according to The MoneyTree Report by PricewaterhouseCoopers and the National Venture Capital Association based on data from Thomson Reuters.

Atlas Venture unveils a $280M pure play biotech startup fund

Atlas Venture is unveiling a new $280 million fund today that will double down on its bet on cutting-edge drugs. Atlas relied on two close industry giants--Amgen and Novartis--and a mix of old and new investors to help raise a fund that easily broke through its $250 million cap.

Galapagos rolls the dice on a $150M IPO, gambling on rheumatoid arthritis drug

A day after Galapagos rolled out promising results for its oral rheumatoid arthritis drug filgotinib on Tuesday, the Belgian biotech confidently rolled out its plan to raise $150 million in an IPO on Nasdaq. And with topline results for a follow-up study expected in a matter of days, Galapagos says it should be poised to jump into Phase III with a $200 million licensing deal from AbbVie expected before the end of this year.

Buzz: OrbiMed mulls $250M Israeli investment fund

OrbiMed Advisors is reportedly laying the groundwork for a second Israeli life science investment fund. And after four years of positive results for its initial government-partnered foray into the country, the big-name biotech VC shop is prepared to try to raise $250 million (€235 million) without state support.

UPDATED: Dominant VC NEA gathers $3B megafund, preps for a wave of biotech rounds

A wave of venture cash continues to flood into the biotech field. And New Enterprise Associates is now back at the crest of that wave. The venture group put out word this morning that it has raised $3.1 billion for two new funds, and if history is any guide, a major part of that money will be earmarked for a new blast of global biotech investments ranging from seed to clinical-stage backing.

Virtual biotechs a hit with investors and, increasingly, buyers

Biotech venture capitalists have increasingly embraced the virtual model, seeding companies with promising assets, tiny staffs and a willingness to outsource. Now, as Reuters notes, a recent Big Pharma buyout signals that the idea is gaining steam among larger players.

Edge Therapeutics hauls in $72.5M for brain injury R&D

New Jersey biotech Edge Therapeutics pocketed $72.5 million in a series of funding rounds, piling up cash as it prepares to take its lead treatment for brain injuries into Phase III development.

Woodford boosts biotech fund max to $1.2B as investors crowd in

When U.K. investment guru Neil Woodford outlined his initial plans for a new, publicly traded tech fund that would seek out up-and-coming biotechs for its portfolio, he pegged the fund as a $300 million player with an option to jump to $750 million if it proved popular.